Neutel 2005.

Methods	multicenter, double‐blind, double‐dummy, randomized, blinded end point, crossover study. After 4 weeks single‐blind placebo run‐in period, patients received chronotherapeutic propranolol and propranolol each for 4 weeks Sample size calculation: not reported carryover effects: not reported no washout period between treatment arms
Participants	Country: not reported Number randomised: 44 gender: 31 men, 13 women mean age: 53.4±8.46 years Ethnicity: Caucasian 27, African American 5, Asian 3, Hispanic 5, Other 4 inclusion criteria: seated DBP of 95–114 mm Hg and a mean daytime ambulatory DBP (8 a.m.to 4 p.m.) of 90–114 mm Hg exclusion criteria: mean DBP ≥115 mm Hg and/or a mean SBP≥200 mm Hg
Interventions	120 mg od chronotherapeutic delayed‐release propranolol (Innopran XL) dosed at bedtime: N=44 120 mg od traditional propranolol (Inderal LA) dosed in the morning : N=44
Outcomes	Mortality: not reported Morbidity: not reported Blood Pressure data:24h BP change, morning (6 am to noon) BP change by 34h ABPM, data was obtained from text. Adverse Events: not reported
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	not reported
Allocation concealment (selection bias)	Unclear risk	not reported
Blinding (performance bias and detection bias) All outcomes	Low risk	double‐dummy
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants were reported. Three patients were excluded, one was excluded by the investigator for being uncooperative and noncompliant with study medication, one for being off study medication for a significant period of time, and one patient was removed for alcohol abuse.
Selective reporting (reporting bias)	Low risk	all outcomes were reported.
Other bias	Unclear risk	carryover effects were not reported